Skip to main content
. 2017 Mar 15;8(24):38294–38308. doi: 10.18632/oncotarget.16203

Figure 3. Targeting CD24 and its inhibitor gene NDRG2 by shRNAs improved chemotherapy sensitivity in vitro and in vivo.

Figure 3

(A, B, C and D) After seeding in matrigel for 5-days, HCC1806 cells were treated with 20 nM docetaxel (DTX) or 1.5 μM doxorubicin (DXR) for 4-days. HCC1937 cells were treated with 0.6 μM docetaxel. P-values of the compared groups were calculated using unpaired t-tests for cell total area. (E) These data show the working scheme for treatments used in tumor xenograft experiments. (F, G, H) These data show results of experiments with five tumors in each treatment group. (I) These data show statistical analyses of tumor shrinkage in the three pairs of experiments. P-values of each paired group were calculated with paired sample t-tests. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars represent SEM. Scale bar, 200 μm.